IFF: Broad-based Q3 growth lifted guidance as portfolio simplification advances amid cost and H&B headwinds

What happened

IFF reported that third-quarter sales and EBITDA, a measure of operating earnings, grew across all continuing businesses, led by Taste and Scent. Nine-month free cash flow was $371m, and the company raised the low end of its full-year guidance as portfolio simplification advanced.

Confirmed

Global impact / market context

Growth across continuing businesses and higher full-year guidance suggest stronger operating performance, while free cash flow indicates cash generated after business spending. However, softness in Health & Biosciences and rising energy and logistics costs could weigh on earnings if they persist.

Analyst inference

The update combines broad-based growth with uneven conditions: Taste and Scent led, but Health & Biosciences remained soft and input and delivery costs increased. For investors, that makes the durability of earnings improvement and the company’s ability to manage costs important to assess.

Analyst inference

What to watch

1. Watch whether the next results show continued sales and EBITDA growth across all continuing businesses, especially whether growth extends beyond Taste and Scent. Analyst inference
2. Track whether Health & Biosciences softness and higher energy and logistics costs continue, since they could reduce earnings despite sales growth. Analyst inference
3. Look for further details on portfolio simplification and full-year guidance, including whether the raised low end is supported by operating results and cash generation. Analyst inference

Evidence

• Original source link unavailable